Healthcare >> Analyst Interviews >> January 13, 2000
TWST: What is it that distinguishes the specialty or emerging COREY DAVIS joined Hambrecht & Quist in 1997 covering the emerging
pharmaceutical industry with an emphasis on mid-cap emerging pharma
names like Alza, Forest, Shire, King, and Medicis. Mr. Davis also
focuses on drug delivery and specialty firms like Emisphere and Neose.
He also co-covers with Alex Zisson the big-cap pharmaceuticals such as
Lilly, Schering-Plough, Merck, Pfizer, and Glaxo. Prior to joining H&Q,
Mr. Davis received a PhD in Molecular Biology from Princeton University.
He graduated Magna Cum Laude in 1991 with High Honors in Biology from
Middlebury College, where he was elected to Phi Beta Kappa. Profile
pharmaceutical companies from the major pharmaceuticals apart from
market capitalization? How is the nature of the business